| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| phorbol 12-myristate 13-acetate | inward rectifier potassium channel kir3.4 | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Hodgkin Disease[MeSHID:D006689] Leukemia Myelocytic Acute[MeSHID:D015470] |
NA | phase 2 | unknown |
| phorbol 12-myristate 13-acetate | calcium-activated potassium channel kca4.1 | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Hodgkin Disease[MeSHID:D006689] Leukemia Myelocytic Acute[MeSHID:D015470] |
NA | phase 2 | unknown |
| phorbol 12-myristate 13-acetate | calcium-activated potassium channel kca4.2 | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Hodgkin Disease[MeSHID:D006689] Leukemia Myelocytic Acute[MeSHID:D015470] |
NA | phase 2 | inhibitor |
| phorbol 12-myristate 13-acetate | calcium-activated potassium channel kca4.2 | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Hodgkin Disease[MeSHID:D006689] Leukemia Myelocytic Acute[MeSHID:D015470] |
NA | phase 2 | unknown |
| phorbol 12-myristate 13-acetate | transient receptor potential cation channel v4 | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Hodgkin Disease[MeSHID:D006689] Leukemia Myelocytic Acute[MeSHID:D015470] |
NA | phase 2 | activator |
| phorbol 12-myristate 13-acetate | transient receptor potential cation channel v4 | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Hodgkin Disease[MeSHID:D006689] Leukemia Myelocytic Acute[MeSHID:D015470] |
NA | phase 2 | unknown |
| click here to return to the previous page | ||||||||